Earnings Call Insights: Rayonier Advanced Materials Inc. (RYAM) Q2 2025
Management View
- CEO De Lyle W. Bloomquist stated that the company faced significant nonrecurring challenges in 2025, leading to a revision of full-year EBITDA guidance to $150 million to $160 million, down from the $215 million to $235 million range at the year's start. He emphasized that these headwinds are "largely behind us as evidenced by the normalizing cellulose specialty orders," and described 2025 as the "trough year and Q2 to be our trough quarter with each subsequent quarter and year expected to show accelerating growth and profitability."
- Bloomquist detailed approximately $59 million in EBITDA headwinds: $21 million from tariff-related uncertainty, $8 million from foreign exchange revaluations, $18 million from operational disruptions, and $12 million in noncash environmental charges. He described the paperboard and high-yield pulp segments as experiencing “higher-than-expected softness.”
- Bloomquist announced a plan to nearly double EBITDA over the next two years relative to revised 2025 guidance, projecting a normalized core EBITDA run rate of approximately $308 million by the end of 2027 and $338 million with the AGE project in 2028. He outlined key drivers: market share gains in cellulose specialties, cost reduction initiatives, and high-return biomaterial projects. "We remain highly confident in the strategy we've set and the unique position we're in to drive meaningful business and shareholder value in the years to come."
- The CEO noted the resolution of disruptive Chinese tariffs, stating, “Currently, our cellulose specialty and dissolving wood pulp exports to China are tariff-free and our paperboard imports into the U.S. remain tariff-free under the USMCA free trade agreement.”
- CFO Marcus J. Moeltner reported, "In the second quarter, revenue was $340 million, down $79 million year-over-year. Operating loss was $1 million, declining by $29 million compared to the prior year. Adjusted free cash flow year-to-date was negative $52 million, while adjusted EBITDA was $28 million, a $40 million decrease compared to the second quarter of last year."
Outlook
- Management revised full year 2025 adjusted EBITDA guidance to $150 million to $160 million, implying second half EBITDA of approximately $105 million to $115 million.
- Adjusted free cash flow guidance is estimated at negative $10 million to $25 million for the full year, with positive free cash flow of approximately $35 million anticipated in the second half.
- Bloomquist described 2025 as a “trough year,” projecting growth in subsequent quarters and years through cost reductions, margin expansion, and strategic investments.
Financial Results
- Revenue for Q2 2025 was $340 million. Operating loss was $1 million. Adjusted free cash flow year-to-date was negative $52 million. Adjusted EBITDA was $28 million.
- In Cellulose Specialties, net sales were $208 million, a $33 million decrease year-over-year. Operating income declined $21 million to $29 million. Adjusted EBITDA margins fell to 22% from 28%.
- Biomaterials net sales were $6 million, with operating income flat at $1 million. Adjusted EBITDA margin declined to 17% from 25%.
- Cellulose Commodities net sales were $59 million. Operating results improved by $12 million, reducing the operating loss to $9 million.
- Paperboard net sales were $47 million, with operating income declining $12 million year-over-year. Adjusted EBITDA for the segment was $5 million, with margins down to 11% from 25%.
- High-yield Pulp net sales were $29 million. Operating loss increased by $8 million to $7 million.
Q&A
- Matthew McKellar, RBC Capital Markets: Asked about the timeline for commercializing dissolving wood pulp fluff in China and its EBITDA impact. Bloomquist responded that material is being sent to customers for trials and "as we approach 2026, that we'll be able to commercialize those going forward," expecting to recapture most share lost due to tariffs.
- McKellar followed up on cost reduction initiatives and Temiscaming execution timing. Bloomquist explained that most of the $24 million in capital will be spent in 2025, with $30 million in value realized in 2026. "We believe that those products will be well positioned to commercialize in '26."
- Daniel Harriman, Sidoti: Queried about outperforming the $30 million incremental EBITDA and capital allocation in 2027. Bloomquist clarified that the $30 million is tied to organic growth and substitution toward specialties, with capital focused on high-return projects and some debt repayment.
- Dmitry Silversteyn, Water Tower Research: Asked about the pace of $30 million cost reduction run rate. Bloomquist indicated the run rate should be achieved as they enter 2026, with most projects completed by the fourth quarter.
- Silversteyn also probed on benefiting from tariffs on EU and Brazil imports. Bloomquist noted a value-over-volume pricing strategy, stating, "The 15% tariff obviously gives us -- will increase our headroom with respect to our competitive positioning."
- On biomaterials growth, Bloomquist expressed high confidence in ramping up projects, citing commercial agreements as a precondition for investment decisions.
Sentiment Analysis
- Analysts pressed on execution timelines, capital allocation, and market share, with a tone that was neutral to slightly cautious, particularly regarding the realization of projected benefits and new product commercialization.
- Management adopted a confident tone in both prepared remarks and Q&A, frequently emphasizing that 2025 headwinds are “largely behind us” and using phrases such as "we remain highly confident" and "exceptional equity returns."
- Compared to the previous quarter, management appears more optimistic, as Q1 was described as “disappointing” with the CEO taking “full responsibility for where we are.” Analyst sentiment remains measured, but management’s tone has shifted from defense to assertive confidence.
Quarter-over-Quarter Comparison
- Guidance was lowered further in Q2, with adjusted EBITDA guidance reduced to $150 million to $160 million from the Q1 range of $175 million to $185 million.
- The narrative shifted from cautious mitigation in Q1 to assertive normalization and future growth in Q2, with the CEO now projecting a doubling of EBITDA over the next two years.
- Management’s tone has moved from acknowledging operational setbacks and tariff uncertainty in Q1 to emphasizing structural advantages, resolved headwinds, and strategic initiatives in Q2.
- Analysts’ questions in both quarters focused on tariffs, market share, operational challenges, and capital allocation, but in Q2, there is greater focus on execution risk and the timing of new initiatives.
Risks and Concerns
- Management cited macroeconomic and internal headwinds, including tariff-related uncertainty, foreign exchange losses, operational disruptions, and noncash environmental charges.
- Challenges in the paperboard and high-yield pulp segments were highlighted as ongoing risks.
- Bloomquist emphasized that while most headwinds are "onetime in nature," indirect effects of tariffs and market softness are not assumed to recover in the current period.
- Analysts raised concerns about execution timing for cost reductions, new product commercialization, and capital allocation priorities.
Final Takeaway
Management conveyed that 2025 is expected to be a low point for RYAM due to extraordinary but largely resolved headwinds. With tariff disruptions easing and new cost reduction and biomaterials initiatives underway, the company now projects substantial EBITDA growth and improved free cash flow in the coming years. The leadership team expressed strong confidence in restoring and expanding profitability, highlighting a robust pipeline of high-return projects and an improved competitive position as key drivers for future shareholder value.
Read the full Earnings Call Transcript
More on Rayonier Advanced
- Rayonier Advanced Materials Inc. (RYAM) Q2 2025 Earnings Conference Call Transcript
- Rayonier Advanced Materials Inc. 2025 Q2 - Results - Earnings Call Presentation
- Rayonier Advanced Materials: Tariff Fears Overdone, Initiate With Strong Buy
- Rayonier Advanced Q2 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on Rayonier Advanced
